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ABSTRACT
Since 1997, highly pathogenic H5N1 avian influenza viruses have circulated in wild and domestic birds and sporadically have 
infected humans. Conventional inactivated vaccines made from these viruses were shown to have decreased HA content and 
immunogenicity compared to seasonal preparations. We assumed that the high pH threshold (5.6-6.0) known for the HA 
conformational change (pH of fusion or activation) of avian highly pathogenic  influenza viruses was the reason of the low stability 
of native HA conformation and affected the vaccine quality. The 58Lys→Ile mutation introduced into the HA2 subunit of the 
HA of A/chicken/Kurgan/5/05 (H5N1) virus decreased the pH threshold of the HA activation. The mutant virus demonstrated 
increased HA stability toward acidic pH and elevated temperature, decreased binding efficiency to the monoclonal antibody IIF4 
that recognizes the HA low pH form, and increased HA resistance to trypsin digestion. Virus with modified HA was less susceptible 
to freezing stress and showed an increased content of immunocompetent HA in inactivated vaccine preparation compared to the 
analogous virus with original HA. Therefore, we have shown a way to increase the quality of inactivated vaccines made from highly 
pathogenic avian influenza viruses.
INTRODUCTION
Since 1997, highly pathogenic avian influenza 
(HPAI) H5N1 viruses have continued to circulate and 
sporadically infect humans, and that poses a pandemic 
threat. Vaccination is recognized as the best strategy 
to prevent virus spreading. Conventional inactivated 
vaccines (whole virus, split virus and subunit) made 
from these viruses were shown to have decreased 
content of immunocompetent hemagglutinin (HA) and 
immunogenicity compared to seasonal preparations. 
The current international guidelines for an inactivated 
seasonal vaccine require one dose containing 15  μg 
of each of three/four HA antigens (two A-strains: 
H1N1 and H3N2 and one/two B-strains: Victoria 
and Yamagata lineages). The requirements of EU 
Committee for Proprietary Medicinal Products (CPMP) 
for effectiveness of inactivated interpandemic vaccine 
include the following specifications: (1) number of 
fourfold increases in anti-HA antibody titers is greater 
than 40%; (2) increase in geometric mean antibody titer 
exceeds 2.5; (3) number of individuals achieving anti-HA 
titer in hemagglutination inhibition (HAI) test >1:40 is 
greater than 70%. For the inactivated split H5N1 vaccine, 
only the two-dose regimen, with 7.5 to 30 μg of HA, 
met the CHMP criteria. Additionally the percentage of 
seropositive subjects was not high enough even when the 
highest dose supplemented with aluminum hydroxide 
adjuvant was applied [1]. For subvirion H5N1 vaccine, 
two doses of 45-90 μg was necessary to get an antibody 
response in more than half of the subjects according 
to either HAI or microneutralization assays (MNA) [2]. 
Slightly better performance was shown for a whole virion 
vaccine, although the antibodies were revealed more 
often by MNA than by standard HAI test and remained at 
low levels [3]. The reason for such a low immunogenicity 
of H5N1 vaccines remains unknown so far.
Our previous studies have demonstrated that certain 
host range mutations in the HA of human influenza 
viruses lead to the enhancement of the pH threshold of 
HA activation which in turn contributed to the decreased 
virus stability and impaired HA antigen content of 
inactivated vaccine preparations [4]. Based on these 
data, we assumed that the higher pH threshold of HA 
conformational change known for the HPAI viruses (5.6–
6.0) versus that for human viruses (5.0–5.4) [5, 6] might 
result in the low stability of the native HA conformation 
and decreased quality of the corresponding inactivated 
vaccines. The goal of this study was to investigate the 
effect of HA conformational stability on the HA antigen 
content and quality of whole virion inactivated influenza 




A Vero (WHO-certified) cell line was obtained from the 
European Collection of Cell Cultures and was adapted 
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and further cultivated at 37°C and 5% CO2 in a serum-
free Opti-pro medium (Invitrogen) containing 4  mM 
L-glutamine (Invitrogen). Madin-Darby canine kidney 
(MDCK; ATCC CCL-34) cells were cultivated at 37°C 
and 5% CO2 in DMEM medium (Invitrogen) comprising 
2% Fetal Bovine Serum (FBS, Invitrogen) and 2  mM 
L-glutamine.
Differentiated cultures of human tracheo-bronchial 
epithelial cells (HTBE cultures) were prepared as described 
before [7, 8]. In brief, commercial primary human cells 
(Lonza) were expanded on plastic, and stored in aliquots. 
These first passage cells were propagated on membrane 
supports (12 mm Transwell-Clear, Corning Inc.) at an 
air–liquid interface (ALI) in serum-free, hormone- and 
growth factor-supplemented growth medium (GM) [7]. 
Fully differentiated 5- to 7-week-old cultures were used 
for the experiments. 
All H5N1 recombinant viruses used in the present 
study were obtained by reverse genetics on Vero cells. 
The generation of reassortant viruses was performed by 
cotransfecting Vero cells with the respective plasmids, as 
described previously [9]. 
The HA and NA sequences of A/chicken/Kurgan/5/05 
HPAI virus were obtained by direct sequencing. The 
GenBank accession numbers for HA and NA are 
DQ449632 and DQ449639. The sequences of HA and 
NA genes for viruses A/Vietnam/1203/04 (VN1203), 
A/Hong Kong/156/97 (HK156), A/Indonesia/5/05 (IND05), 
A/Anhui/1/05 (ANH01), A/turkey/Turkey/1/05 (tkTK01) 
were taken from the GenBank. All of the sequences 
were cloned into the pHW2006 plasmid, a synthetically 
produced analogue of pHW2000 [10]. The HA polybasic 
cleavage site was replaced by the more stable sequence 
TETR/GLF described for low pathogenic avian influenza 
viruses [11]. The 58Lys→Ile mutation in the HA2 
subunit of A/chicken/Kurgan/5/05 HA was introduced 
by mutagenesis kit (Stratagene, Germany). Reassortants 
KG05 and KG05-58 inherited HA and NA genes from 
A/chicken/Kurgan/5/05 virus and genes coding six 
internal proteins from the A/PR/8/34 (H1N1) (PR8) strain 
and differed by a single mutation K58I in the HA2. 
Additionally, a number of reassortants were 
generated containing HA and NA genes from VN1203, 
HK156, IND05, ANH01, tkTK01 viruses in combination 
with other genes from the IVR-116 vaccine strain. Virus 
IVR-116 is a reassortant containing HA and NA genes 
from the virus A/New Caledonia/20/99 (H1N1), PB1 
gene from A/Texas/1/77 (H3N2) and all other genes 
from PR8. 
Epidemic viruses A/Brisbane/59/07 (H1N1) (BR59) 
and A/Brisbane/10/07 (BR10) were obtained from NIBSC 
(National Institute of Biological Standards and Controls, 
GB). The primary isolate A/Vienna/25/07 (VI25) 
antigenically characterized as A/Wisconsin/67/05-like 
(H3N2) was provided by the Institute of Virology, Vienna, 
Austria. Human primary isolate A/St. Petersburg/14/10 
(H1N1pdm) (SP14) and H5N3 low pathogenic virus A/
duck/Singapore/3/97 (dkSG03) was provided by Research 
Institute of Influenza, Saint Petersburg, Russia.
Virus propagation and titration
Egg-derived viruses were propagated in the allantoic 
cavity of 9–11-day old embryonated specific pathogen 
free (SPF) chicken eggs (CE). Allantoic fluid was collected 
48 h post infection. Vero or MDCK cells were inoculated 
with viruses diluted in OptiPRO SFM medium and 
incubated at 37°C for 30  min. Cells were cultivated in 
OptiPRO SFM supplemented with 4  mM L-glutamine, 
250  ng/ml Amphotericin B (Bristol-Myers Squibb, 
Austria) and 5 μg/ml trypsin (Sigma–Aldrich, Austria) at 
37°C with 5% СО2 for 72  h. Infectious virus titers were 
determined on CE, Vero or MDCK cells and expressed 
in 50% Embryo Infective Dose (EID50/ml), calculated 
according to Reed and Muench method [12].
Hemolysis assay
Titers of investigated viruses were adjusted to 128 HAU. 
Diluted viruses (50 μl) were mixed with 150  μl of 1% 
chicken red blood cells (cRBC) and incubated on ice for 
1 h to allow virus to bind. Mixtures were centrifuged at 
400  g and supernatants removed. After the addition of 
250  μl of 0.15  M sodium citrate buffered saline to the 
solid precipitate at various pH values (from 5.1 to 7.0) 
mixtures were incubated at 37°C for 1  h and finally 
centrifuged at 400 g. Then, 200 μl of supernatants were 
transferred to 96-well flat-bottom plates and the amount 
of hemoglobin released by virus-cell fusion induced 
hemolysis was determined by measuring the optical 
density (OD) at 415  nm. The presented results are the 
mean values of three replicates at the indicated pH plus/
minus standard deviation (SD).
Thermal stability
Viruses were incubated in a thermo block at 58°C for 
different time intervals from 0 to 60  min. In parallel, 
control samples were incubated on ice for 60  min. 
Subsequently, the HA titer was measured with a 0.5% 
suspension of cRBC.
Characterization of virus HA conformation 
by binding with IIF4 antibodies 
The assay protocol was adapted from Vareckova et al. 
[13]. Briefly, maxisorp 96-well plates (Nunc, Denmark) 
were coated with 40  HAU/well of virus diluted in PBS. 
After overnight incubation at 4°C, the wells were treated 
with 300 μl of MES-based buffers, adjusted to pH in the 
range from 4.6 to 7.5 and incubated at 37°C for 15 min. 
After buffer removal, the wells were washed with PBS 
and blocked with 0.5% I-BLOCK and 0.5% Tween 20 in 
PBS. The presence of HA in low-pH conformation was 
assessed by 1 h incubation of plates with 100 ng/well 
of IIF4 monoclonal antibodies (Dr. E. Vareckova, Slovak 
Academy of Sciences) at room temperature, followed 
by detection with HRP labeled goat anti-mouse IgG(γ) 
(KPL, USA). The HRP enzyme activity was assayed with 
the Peroxidase Substrate TMB (KPL, USA). The enzyme 
reaction was stopped by the addition of 1 N H2SO4 followed 
by the OD measurement at 450 nm. The reported results 
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are the mean values of 4 replicates at the indicated pH 
plus/minus SD.
Infectivity of viruses at different pH
Vero cell monolayers were inoculated with viruses 
diluted to the multiplicity of infection (MOI) of 2 in MES 
infection buffer containing 250  ng/ml Amphotericin B, 
adjusted to pH 5.2, 5.4, 5.6, 5.8, 6.0, or 7.5, for 30  min 
at 37°C. After that, the inoculum was removed and the 
cells were incubated in OptiPRO SFM containing 4 mM 
L-glutamine in the presence of 5% CO2 at 37°C for 5 h. 
Then, the cells were fixed with 4% paraformaldehyde 
(Sigma-Aldrich, Austria), permeabilized with 1% Triton 
X-100 (Merck, Germany), and incubated overnight with 
1% BSA (Sigma-Aldrich, Austria) in PBS. After that, the 
cells were stained with mouse anti-influenza virus A NP 
antibodies (Millipore, USA) followed by treatment with 
goat anti-mouse Alexa Fluor 488 antibodies (Invitrogen, 
Austria). The infected cells were detected by fluorescence 
microscopy.
HTBE cultures were inoculated with virus suspensions 
in MES buffers (pH 5.6, 5.8, 7.5) at MOI~1 for 1  h at 
35°C. After removal of the inoculum, the cultures were 
washed 3  times with PBS and incubated at air-liquid 
interface for an additional 8 h. Then, the cultures were 
fixed and immunostained for viral NP as described above 
using peroxidase-labeled secondary antibodies and DAB 
peroxidase substrate. 
MDCK cells were inoculated by viruses (MOI 2) in 
MES buffer at different pH as described above. After 
5  h of incubation, the cells were collected from the 
solid support surface by 0.2% solution of trypsine-
EDTA (“Cellgro”) and fixed by Fix/Perm buffer (BD 
Cytofix/Cytoperm Plus Kit). After that, the cells were 
treated with 1% solution of fetal calf serum in PBS 
overnight, permeabilized and stained with FITC labeled 
anti-influenza NP antibodies (“Imagen”, UK). The 
concentration of the infected cells was measured by 
flow cytometry using EXPO 32 software (Immunotech 
Inc., a Beckman Coulter company).
Preparation of H5N1 inactivated vaccine samples
Viruses were grown in the embryonated chicken eggs or 
cell cultures (Vero, MDCK) as described above. Harvested 
virus suspensions were mixed with formalin (final 
concentration 0.015%) and incubated at 32°C for 24.5 h 
for complete virus inactivation. Virus containing fluids 
were clarified by low speed centrifugation, pelleted by 
ultracentrifugation and then resuspended in phosphate-
buffered saline (PBS) pH 7.2. The virions were purified 
in a 20-60% sucrose gradient and pelleted again. Finally, 
the pellets were resuspended in PBS. 
Determination of HA content in vaccine 
preparations
The influenza HA antigen content in the vaccine 
preparations was determined by single radial immuno-
diffusion (SRID) assay according to Wood et al. [14].
Treatment with trypsin
The purified concentrated virus preparations were 
diluted to a concentration of 15 μg/ml protein and treated 
with 100 μg/ml trypsin (TPCK-treated, Sigma) in PBS at 
pH 7.4 and 37°C for 2 h. Then, each sample was mixed 
with a loading buffer, heated for 5 min at 95°C and the 
viral proteins were separated in a polyacrylamide gel by 
SDS-PAGE. Qubit Protein Assay (Invitrogen) was used to 
estimate the amount of protein in each preparation.
RESULTS
Avian H5N1 influenza viruses are less stable 
at acidic pH than human viruses
To find out whether the H5N1 viruses are less stable at 
acidic pH than human seasonal strains, we compared 
their infectivity at acidic pH in differentiated cultures 
of human tracheo-bronchial epithelial cells (HTBE). 
Primary human isolates VI25 (H3N2), SP14 (H1N1pdm) 
and the reassortant VN1203 (H5N1) virus were adjusted 
to a similar MOI and mixed with acidic (pH 5.6 and 5.8) 
or neutral (pH 7.5) buffer, followed by inoculation into 
the cultures. In 1 h, the buffer was changed to the neutral 
medium and viruses were further incubated for 8  h at 
37°C. The effectiveness of the infection was determined 
by visualization with anti-influenza nucleoprotein (NP) 
antibodies. As shown in Fig. 1, both human viruses VI25 
and SP14, infected HTBE cultures at pH 5.6 and 5.8 while 
virus VN1203 infected human cells at pH 7.5 and pH 5.8, 
but was not infectious at pH 5.6. 
In order to check more H5N1 viruses, the reassortants 
with HA and NA genes from the avian viruses of different 
clades, such as HK156, (clade 1), IND05 (clade 2.1), ANH01 
(clade 2.2), tkTK01 (clade 2.2), and KG05 (clade 2.2), were 
generated. The infectivity of obtained viruses at different 
pH was compared in the analogous experiment in MDCK 
cells at pH range 5.2-7.5 followed by the determination of 
the number of infected cells by flow cytometry (Fig. 2A). 
The virus was considered stable if it had infected more 
than 50% of the cells at the indicated pH. 
We found that human strains BR59 (H1N1) and BR10 
(H3N2) were the only ones infecting cells at pH ≥ 5.4 
(62% and 68% respectively). Viruses dkSG03 (H5N3) and 
HK156 (H5N1) infected MDCK cells at pH ≥ 5.6 (74% and 
76% at pH 5.6, respectively), and the rest of H5N1 strains 
were infectious only at pH ≥5.8. Based on the obtained 
results the stability chart was constructed (Fig. 2B). 
Stability of KG05 and mutant KG05-58 at low pH 
and elevated temperature
It was shown that the substitution 58Lys→Ile introduced 
into the HA2 subunit of H5N1 avian virus decreases 
the pH threshold of the HA conformational change and 
increases virus stability toward acidic pH and elevated 
temperature [15-18]. We introduced this change in the HA 
of KG05 (Fig. 3). As a result, the constructed reassortant 
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Fig.  1. Infectivity of viruses at different pH in HTBE 
cultures. 
Wells with differentiated cultures of human tracheo-
bronchial epithelial cells were infected with SP14 
(H1N1pdm), VI25 (H3N2) seasonal human viruses 
and with H5N1 virus (VN1203) at a different pH. The 
infected cells were visualized by immunostaining for 
viral NP.
Fig. 2. Infectivity of viruses at different pH in MDCK cells. 
(A) Viruses were mixed with MES buffer at indicated pH and 
used for infection of MDCK cells at MOI 2. After incubating 
for 5  h, influenza NP was visualized by immunostaining 
followed by flow cytometry. The indicated numbers show the 
percentage of infected cells. (B) The diagram of stability of 
studied influenza viruses toward low pH. 
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KG05-58 differed from the original virus KG05 by a single 
58Lys→Ile mutation in HA protein. Both viruses KG05 
and KG05-58 demonstrated high growth in CE with the 
maximal HA titer of 512 HAU/50 μl and infectious activity 
of 9.0 logEID50/ml (Fig. 4 A, B).
To investigate the effect of the introduced mutation 
on the pH threshold of the HA activation, viruses were 
compared in a hemolysis assay. As shown in Fig. 5A, virus 
KG05 triggered fusion at pH 5.6–5.7, while the same 
fusion rate for the mutant virus KG05-58 was observed 
at the pH 5.3-5.4. 
Next, we compared the HA binding activity of KG05 
and KG05-58 viruses to the IIF4 monoclonal antibody 
known to recognize the HA low pH conformation. The 
results show that IIF4 bound efficiently to the KG05 virus 
at pH 5.6 while the equivalent binding of IIF4 to KG05-58 
virus was observed at pH 5.3 (Fig. 5B). 
Then we investigated whether the mutant virus was 
more stable at an elevated temperature. Viruses were 
incubated at 58°C for various time intervals (from 0 to 
60  min) and analyzed for the residual HA activity. The 
data presented in Fig.  5C, show that the complete HA 
inactivation for the virus KG05 was observed in 20 min, 
while for the mutant KG05-58 in 40 min.
Investigation of the virus infectivity under acidic 
conditions in Vero cells also revealed that the mutant 
KG05-58 gained the resistance to acidic pH compared 
to the original virus and infected Vero cells at pH ≥ 5.4, 
whereas the KG05 virus was infectious at pH ≥ 5.8 
(Fig. 5D).
The obtained data demonstrate that introduction of 
58Lys→Ile mutation leads to enhancement of HA protein 
stability of KG05 influenza virus toward an acidic pH and 
elevated temperature.
Characterization of mutant and original viruses 
by electron microscopy
The structure and morphology of the purified inactivated 
KG05 and KG05-58 viral particles was compared by 
means of electron microscopy. In addition to native virus 
preparations, we compared samples after one cycle of 
freezing/thawing. As it is shown in Fig. 6, the HA spikes of 
both viruses appeared as rods with a well-defined length. 
However, after one cycle of freezing/thawing a number 
of spikes of the KG05 virus disappeared and some of 
the remaining spikes were damaged. In contrast to that, 
the consistency of spikes and the virion morphology of 
KG05-58 did not change. 
Thus, in the course of the freezing/thawing process, 
the KG05 virus was significantly destroyed, whereas the 
mutant virus KG05-58 was unaffected by this process. 
Susceptibility of original and mutant viruses 
to trypsin digestion
The HA protein in its native state is resistant to the 
proteolysis by trypsin and other proteases, but becomes 
susceptible to it in low pH conformation [20]. In order 
to reveal the HA structural rearrangements after one 
cycle of freezing/thawing the HA integrity was assessed 
by SDS-PAGE before and after trypsin treatment. Virus 
preparations KGO5 and KGO5-58 were adjusted to the 
same protein concentration and treated with trypsin. 
The results show that, without trypsin digestion, no 
difference in the pattern of HA specific bands between 
viruses was observed (Fig.  7). Treatment with trypsin 
resulted in the disappearance of HA band for KG05 
while the HA of mutant virus KG05-58 appeared to be 
resistant to trypsin digestion. This observation confirms 
that virus KG05 after one cycle of freezing/thawing 
Fig. 3. Side view of the HA molecule three-dimensional structure. 
Residues responsible for protein stability are highlighted. The figure was generated with the Chimera v. 1.5.3 [19] structure 2IBX (Protein 
Data Bank). 
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Fig. 4. The kinetic of KG05 and KG05-58 growth in CE
(A) The infectious titer of viruses grown in CE. (B) The HA titer of viruses grown in CE at different time points. The results are presented 
as the mean of three independent experiments.
Fig. 5. The stability toward low pH and elevated temperature of KG05 and KG05-58 viruses
(A) Hemolysis assay of KG05 and KG05-58 made with chicken erythrocytes. (B) Binding affinity of the monoclonal antibody IIF4 to the HA 
of KG05 and KG05-58. (C) Thermal stability of KG05 and KG05-58 at elevated temperatures. (D) Infectivity of indicated viruses under acidic 
conditions in Vero cells at pH range 5.2-7.5. 
contains more HA in the low pH conformation sensitive 
to trypsin compared to the mutant virus KG05-58. 
Measurement of HA content in vaccine preparations 
The most common test to estimate the inactivated 
influenza vaccine potency is the SRID. This assay measures 
the amount of the immunocompetent HA reacting with 
antibodies present in the standard antiserum. To find 
out whether the substrate used for the virus propagation 
has any impact on the vaccine potency, we propagated 
KG05 and KG05-58 in CE, Vero and MDCK cell lines and 
determined the relative HA content of each inactivated 
virus preparation (Table  1). All virus-containing fluids 
were inactivated, purified, and concentrated by the same 
procedure and then diluted to the protein content of 
100 μg/ml. The results show that the relative amount of 
immunocompetent HA in the KG05 grown in MDCK was 
1.8 times lower than that of the mutant KG05-58 (Fig. 8C). 
For the virus grown in the Vero cell line, the relative HA 
content for the mutant KG05-58 was 1.14  times higher 
than that of the KG05 (Fig.  8B). Inactivated viruses 
produced in CE did not show any substantial difference 
in HA content (Fig. 8A). It is interesting to note that the 
total protein amount in preparations derived from the 
modified virus KG05-58 grown on MDCK and Vero was 
1.9 and 1.5  times higher, respectively, than that of the 
original KG05 virus (Table 1). 
DISCUSSION
In the current study, we investigated the effect of the HA 
conformational stability of HPAI H5N1 viruses on the 
properties of inactivated vaccine preparations. We found 
that H5N1 viruses of different clades are more susceptible 
to acidic inactivation than the human BR59 (H1N1) and 
BN10 (H3N2) seasonal strains.
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Fig. 6. Electron microscopy of KG05 and KG05-58 viruses 
Purified inactivated viruses were subjected to one cycle of freezing/thawing and then analyzed by electron microscopy. Arrows indicate 
damaged, rare, and shortened spikes of viral HA.
Fig. 7. Sensitivity of viruses to trypsin digestion after one freezing/
thawing cycle. 
KG05 and KG05-58 viruses with original and mutated HA were 
purified, subjected to one cycle of freezing/thawing and treated 
with 100  μg/ml of trypsin for 2  h at 37°C. Viral proteins were 
separated by SDS-PAGE under non-reducing conditions.
We showed that the H5N1 virus stability could be 
improved by the introduction of a single amino acid 
substitution 58Lys→Ile in the HA2 subunit of HA 
molecule. The amino acid at position 58 is located in the 
HA2 coiled-coil domain and presumably stabilizes the 
HA trimer structure providing additional intermolecular 
hydrophobic interactions with the neighboring 
monomers (Fig. 3) [21]. Consequently, the HA of mutant 
virus KG05-58 underwent fusion with erythrocytes at 
pH close to that of the human viruses (pH 5.0–5.4) [22]. 
The mutant virus also became more resistant to elevated 
temperature and trypsin digestion than the original 
virus. Finally, the introduced mutation contributed to 
the resistance of HA spikes to freezing/thawing stress 
induced by pH shift because of the changes of the local 
salt concentration of PBS buffer during freezing [23]. 
As a result, the purified virus preparation of mutant 
virus contained more immunocompetent HA as measured 
by SRID assay compared to the preparation made from 
the original virus. The observed difference depended 
on the substrate used for virus propagation. The major 
increase was detected for the virus preparations produced 
on MDCK cells. The corresponding effect for the Vero-
grown strains was less pronounced. No difference was 
revealed for viruses grown in CE. Since the total protein 
content for the mutant and original viruses was equal, 
it is reasonable to explain the decreased amount of 
immunocompetent HA in the original virus preparation 
by the HA “damage” in the course of purification and 
concentration steps. The absence of difference for the 
egg-grown viruses could be explained by the higher pH 
(8.0–8.3) of the allantoic fluid in comparison to that of 
the cell media (pH 7.4) and the possible stabilizing action 
of the allantoic proteins [24].
Harvey et al. [25] showed that H5N1 vaccine 
preparations contain up to 22% less immunocompetent 
HA than vaccines prepared from the human influenza 
viruses. The authors concluded that this effect is partially 
due to the relatively lower HA protein content in the 
H5N1 virus particles. According to our results, the low 
content of immunocompetent HA of H5N1 vaccines is 
rather attributed to the HA conformational instability of 
H5N1 viruses. 
The natural structure of HA represents the 
metastable state, which is triggered by acidic pH 
to the thermodynamically more stable irreversible 
conformation by overcoming the kinetic barrier. As a 
result the HA antigenic determinants located on the 
surface of the HA1 globular part and responsible for the 
development of the neutralizing antibodies, are being 
masked, while the HA2 epitopes, hidden in the natural 
HA structure, become exposed. The HA2 epitopes are 
known to induce antibodies, which do not react in HAI 
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Substrate Virus Viral Suspension Purified inactivated virus preparations
Volume, ml HA Titer Volume, ml HA Titer Total Protein, mg/ml
CE KG05 100 128 0.5 12800 1.78
KG05-58 100 128 0.5 12800 1.92
Vero KG05 100 16 0.4 400 0.40
KG05-58 100 16 0.4 800 0.61
MDCK KG05 100 16-32 0.25 320 0.30
KG05-58 100 16 0.25 640 0.59
Table 1. The HA titers and total protein contents of KG05 and KG05-58 purified inactivated virus preparations grown in different substrates.
Fig. 8. The HA content in the KG05 and KG05-58 purified virus preparations measured by SRID assay. 
Relative HA content in purified inactivated virus preparations grown in different substrates was measured as precipitation area (mm2): (A) 
CE, (B) Vero cells, (C) MDCK. Viruses were adjusted to the same protein content.
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test. Thus, the low HA conformational stability of H5N1 
viruses might be related to the decreased amount of 
antibodies reacting in the HAI test revealed for H5N1 
vaccines [26, 27]. Our assumption is confirmed by Khurana 
et al. [28], who reported the enhanced production of 
the antibodies to the HA2 antigenic determinants in 
patients vaccinated with the H5N1 vaccine. The authors 
showed that the antibodies in the sera of individuals 
had a low binding affinity to the properly folded HA1 
subunit (peptide 28-319), but showed high reactivity 
with the HA2 epitopes. The amount of neutralizing 
antibodies directed to the native HA increased when the 
vaccine was administered together with adjuvant MF59. 
It could possibly be explained by the stabilizing action 
of the oil adjuvant MF59.
The HA conformational change could be triggered not 
only by pH shift but also by elevated temperature and 
denaturation agents [29]. Therefore, the H5N1 viruses 
are highly susceptible to different destabilizing factors 
during the vaccine production, such as centrifugation, 
filtration, chromatography, chemical disruption, and 
storage. 
It should be mentioned that the low HA conformational 
stability of H5N1 viruses increases the tendency of virions 
to form aggregates by interaction of the hydrophobic 
HA2 domens [30]. The presence of aggregates in vaccine 
preparations is extremely undesirable because they are 
known to induce additional side effects in humans after 
the vaccination [31]. 
Earlier, we have shown that the efficiency of 
intranasal vaccination with the live virus also depends 
on the HA conformational stability [15, 32]. The correct 
native HA composition is critical for the effective virus 
attachment and penetration in the epithelial cells of the 
upper respiratory tract and assures the higher immune 
response. These results are in full agreement with the 
data published by Imai et al. [33], who discovered that 
the increased pH of HA activation of the avian highly 
pathogenic virus strains is one of the factors for their low 
airborne transmission in ferrets. 
In summary, we showed that the decreased content 
of the immunocompetent HA in the HPAI vaccine 
preparations is determined by the high HA activation pH 
leading to the low HA conformational stability of these 
viruses. This could also explain the low immunogenicity 
of the H5N1 vaccines, but the latter assumption requires 
further investigation. 
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